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Abstract
Background: Diagnosis and prognosis in breast cancer are mainly based on histology and
immunohistochemistry of formalin-fixed, paraffin-embedded (FFPE) material. Recently, gene expression
analysis was shown to elucidate the biological variance between tumors and molecular markers were
identified that led to new classification systems that provided better prognostic and predictive parameters.
Archived FFPE samples represent an ideal source of tissue for translational research, as millions of tissue
blocks exist from routine diagnostics and from clinical studies. These should be exploited to provide
clinicians with more accurate prognostic and predictive information. Unfortunately, RNA derived from
FFPE material is partially degraded and chemically modified and reliable gene expression measurement has
only become successful after implementing novel and optimized procedures for RNA isolation,
demodification and detection.
Methods: In this study we used tissue cylinders as known from the construction of tissue microarrays.
RNA was isolated with a robust protocol recently developed for RNA derived from FFPE material. Gene
expression was measured by quantitative reverse transcription PCR.
Results: Sixteen tissue blocks from 7 patients diagnosed with multiple histological subtypes of breast
cancer were available for this study. After verification of appropriate localization, sufficient RNA yield and
quality, 30 tissue cores were available for gene expression measurement on TaqMan® Low Density Arrays
(16 invasive ductal carcinoma (IDC), 8 ductal carcinoma in situ (DCIS) and 6 normal tissue), and 14 tissue
cores were lost. Gene expression values were used to calculate scores representing the proliferation
status (PRO), the estrogen receptor status and the HER2 status. The PRO scores measured from entire
sections were similar to PRO scores determined from IDC tissue cores. Scores determined from normal
tissue cores consistently revealed lower PRO scores than cores derived from IDC or DCIS of the same
block or from different blocks of the same patient.
Conclusion: We have developed optimized protocols for RNA isolation from histologically distinct areas.
RNA prepared from FFPE tissue cores is suitable for gene expression measurement by quantitative PCR.
Distinct molecular scores could be determined from different cores of the same tumor specimen.
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Diagnosis and prognosis of breast cancer are still mainly
based on clinical, histological and immunohistochemical
parameters, which are at best semi-quantitative [1,2].
Recently, molecular characterization of breast cancer has
greatly increased the understanding of biological path-
ways that are altered during neoplastic transformation.
Molecular markers have a great impact on elucidating the
biological variance within tumors, they allow new and
more accurate classifications and they have the potential
to improve diagnosis, estimation of prognosis and treat-
ment decisions in individual patients [3-6].
Most gene expression studies are based on fresh frozen
material which, in most instances, is not readily available,
as surgical samples are usually fixed in formalin. Unfortu-
nately, RNA derived from formalin-fixed, paraffin-embed-
ded (FFPE) material is considerably fragmented and
chemically modified, often impairing gene expression
measurement using standard procedures. We developed a
simple and robust protocol for RNA isolation and partial
de-modification from standard FFPE sections and docu-
mented that the isolated RNA is suitable for gene expres-
sion measurement by quantitative reverse transcription
PCR (QRT-PCR) [7,8]. However, RNA isolated from tissue
sections may not be representative for a tumor as the pro-
portion of normal tissue in a section may be significant.
To circumvent this problem, we used tissue cores as pre-
pared for the construction of tissue microarrays (TMA).
TMAs allow to analyze hundreds of archival tissue sam-
ples simultaneously [9]. For a TMA, individual cores are
punched from representative areas of a large series of FFPE
tissue blocks and re-assembled on a single recipient paraf-
fin block. Sections from TMA blocks are processed by
staining, immunohistochemistry or in situ hybridization
like regular tissue sections, revealing results from up to
1000 individual tissue cores present on a single array
[10,11].
We used such tissue cores as source of material for RNA
isolation. In contrast to sections which represent all tissue
types present in the block, tissue cores have the great
advantage that they can be taken very precisely from the
area of interest within an individual tissue block [12,13].
In the present study, tissue cores were taken from normal
and cancerous tissue of the same block and gene expres-
sion was measured. We compared the level of expression
of various genes between invasive ductal carcinoma
(IDC), ductal carcinoma in situ (DCIS) and regions of his-
tologically normal breast epithelium in single tissue
blocks.
Methods
Tissue specimens and generation of tissue cores
Breast cancer specimens from 7 patients diagnosed with
ductal carcinoma were retrieved from the files of the Insti-
tute of Pathology, University of Bern. Tissue samples were
fixed with 4% neutralized formalin and embedded in par-
affin. Sections from each of a total of 16 tissue blocks (1
to 4 blocks per patient) were stained with hematoxylin
and eosin and regions containing IDC, DCIS and normal
breast epithelium were marked on each slide and the cor-
responding paraffin block (Fig. 1A and 1B). Three to 5 tis-
sue cores were punched from each area of interest (1 to 5
areas in each block) using a manual tissue microarrayer
(Beecher Instruments, Sun Prairie, WI, USA). In total, 3 to
5 tissue cores were taken from 44 individual areas. Cylin-
ders had a diameter of 0.6 mm and the length of the cores
varied between 1 and 3 mm resulting in approximately
0.3 to 1 mg tissue per core (Fig. 1E). After taking tissue
cores, RNA was isolated from five 10 μm thick serial sec-
tions that were collected from each tissue block at several
levels separated by 400 μm. Tissue was evaluated by
hematoxylin and eosin staining of sections at each level
and the localization of tissue cores was verified micro-
scopically within tumor and normal tissue (Fig. 1C and
1D). Six tissue cores were excluded from further experi-
ments because they did not represent tissue from the
appropriate area of interest. Histopathological character-
istics of each tumor, number of layers per block and
number of areas punched and analyzed are summarized
in Table 1. All patients gave written informed consent to
use their material. The study was performed on the basis
of an approval by the ethical committee of the Canton
Bern, Switzerland.
RNA isolation and expression analysis
Entire tissue cores or 5 tissue sections were de-paraffinized
with Neo-Clear (Merck, Darmstadt, Germany), washed
with ethanol and dried. RNA was isolated as described
previously [8] using the following modifications: 500 μl
of lysis buffer containing approximately 1 μg/μl Protein-
ase K (Roche Diagnostics, Mannheim, Germany) was
used. Tissue was homogenized in a Mixer Mill at 20 Hz for
4 min and digested at 55°C for 1 hour. RNA was de-mod-
ified and purified on silica-based columns as described
previously [8]. RNA quantity and quality were assessed on
a ND-1000 spectrophotometer (NanoDrop Technologies,
Wilmington, DE, USA) and on an Agilent 2100 Bioana-
lyzer (Agilent Technologies, Inc., Santa Clara, CA, USA).
Five tissue cores were excluded from subsequent experi-
ments due to insufficient RNA yield (less than 0.45 μg).
The quality of each RNA sample was further tested by
QRT-PCR using TaqMan assays for GUSB, RPLP0 and UBB
(Applied Biosystems, Foster City, CA, USA) (Table 2) and
a One-Step QRT-PCR protocol according to the recom-Page 2 of 7
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CA, USA). QRT-PCR was performed on an Applied Biosys-
tems 7500 instrument in Fast mode (50°C for 15 min,
95°C for 2 min, followed by 45 cycles of 95°C for 3 sec
and 60°C for 30 sec). Three RNA samples were excluded
from further analyses because the mean Ct value of the 3
control genes was considerably higher than the mean of
all other samples.
For the remaining 30 RNA samples gene expression levels
were measured for control genes and for genes associated
with proliferation, estrogen receptor function and HER2
using TaqMan® Low Density Arrays (TLDA; Applied Bio-
systems) on an Applied Biosystems 7900 HT instrument.
A list of assays used in this study is given in Table 2. Indi-
vidual reactions were carried out with 2 ng of total RNA
using the following cycling conditions: 50°C for 15 min,
95°C for 2 min, followed by 40 cycles of 95°C for 10 sec
and 60°C for 30 sec.
Table 1: Breast tissue specimens used in the study
Patient No. Histological grade IHC Block No. of layers No. of tissue cores1
ER PgR Her2 Ki-67 LI (%) IDC DCIS N
1 3 + + - 70 1.1 2 3/3 1/1 1/1
2 2 + + - n.d. 2.1 3 2/2 1/1 1/1
3 3 + + + 50 3.1 2 3/3 1/1 0/12
4 2 + - + 30 4.1 3 3/3 1/1 1/1
4.2 3 1/1
4.3 3 0/13
5 2 + + + 5 5.1 3 2/2
5.2 2 1/1 0/13
5.3 1 0/14 0/13 0/14
5.4 2 1/1
6 3 - - + 80 6.1 3 1/22 1/1 0/22
6.2 3 1/24
6.3 3 0/14
6.4 3 1/22
7 2 + + - 10 7.1 3 2/34
7.2 1 1/24
IHC = immunohistochemistry; ER = estrogen receptor; PgR = progesteron receptor; Her2 = Her2/neu; Ki-67 LI = Ki-67 labeling index; N = normal 
tissue; n.d. = not determined; 1 = number of tissue cores analyzed/total number of tissue cores punched; 2 = tissue cores excluded from gene 
expression measurement due to insufficient RNA yield; 3 = tissue cores excluded from gene expression measurement due to insufficient RNA 
quality; 4 = tissue cores excluded from gene expression measurement due to inappropriate localization of the core.
FFPE material before and after punchingigure 1
FFPE material before and after punching. Hematoxylin and eosin-stained tissue sections and paraffin block of patient 4 
are shown before and after punching tissue cores. Areas of IDC (red), DCIS (blue) and normal tissue (green) were marked on 
the original tissue section (A) and on the corresponding paraffin block (B). Tissue cores (E) were taken with a tissue microar-
rayer instrument. Thereafter, sections were made from the remaining block and a control staining and RNA isolation were 
done at ~400 μm intervals through the block (C and D). The area containing DCIS was lost after ~400 μm and tissue cores 
contained fat instead of tumor tissue. It was known from previous experiments that very little RNA can be isolated from fat 
cells. Therefore, expression measurements in tissue cores containing fat besides tumor tissue are not compromised.Page 3 of 7
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Raw data were recorded with the SDS software of the
instruments. Delta cycle threshold (Ct) values were deter-
mined as the difference between the Ct of each test gene
and the mean of RPLP0, UBB and GUSB (control genes).
Scores representing the proliferation status (PRO), the
estrogen receptor status (ER) and the HER2 status (HER2)
were computed from 5 genes associated with proliferation
(AURKA, MYBL2, CCNB1, MKI67 and BIRC5), 4 genes
related to estrogen receptor function (ESR1, PGR, BCL2
and SCUBE2) and 2 genes related to HER2 (ERBB2 and
GRB7). The procedure for calculating scores was described
previously [8].
Results and Discussion
Sixteen tissue blocks from 7 breast cancer patients diag-
nosed with multiple histological subtypes were available
for this study. In total, 44 tissue cores were taken from
areas representing 19 IDC, 11 DCIS and 14 areas contain-
ing normal tissue. After verification of appropriate locali-
zation, sufficient RNA yield and quality, 30 tissue cores
were available for gene expression measurement on
TLDAs (16 IDC, 8 DCIS and 6 normal tissue) (Table 1).
Total RNA was isolated from tissue cores and from sec-
tions as described in Methods and according to the previ-
ously established protocol [8]. RNA yield was assessed
spectrophotometrically (Fig. 2A). For a better comparison
of recoveries from individual samples, the RNA yield was
converted to numbers corresponding to 3 tissue cores
with an average length of 3 mm or to 1 tissue section (10
μm thick), respectively. The mean recovery from tissue
cores was 4.0 μg (range 0.3 – 8.5) for IDC, 2.3 μg (0.8 –
6.2) for DCIS and 0.8 μg (0.2 – 2.2) for normal tissue. The
corresponding mean yield per tissue section was 2.3 μg
(range 0.3 – 6.3). The quality of each RNA was tested on a
Bioanalyzer (Fig. 2B) and by measuring gene expression
of 3 control genes (GUSB, RPLP0 and UBB) by QRT-PCR
(Fig. 2C). Bioanalyzer results revealed fragment lengths
between 100 and 2000 bp with mean fragment lengths
around 500 bp which is typical for good quality RNA from
FFPE material. The mean of all 3 control genes was Ct =
24.3 (range 23.8 – 25.2) for IDC, Ct = 24.8 (23.6 – 28.5)
for DCIS and Ct = 26.0 (23.9 – 30.3) for normal tissue
cores. Corresponding mean expression for tissue sections
revealed Ct = 25.1 (range 23.4 – 26.3).
Gene expression levels were measured on TLDAs. Gene
expression of each test gene was normalized using the
mean of RPLP0, GUSB and UBB as reference. Putative
control genes were previously compared by QRT-PCR
with RNA of more than 80 matched samples of fresh fro-
zen and archival FFPE material, which revealed that
GUSB, RPLP0 and UBB are the 3 most stably expressed
genes in breast cancer that can be measured reliably by
QRT-PCR (Antonov et al., manuscript in preparation).
Scores were computed from genes related to PRO, ER and
HER2 status as described in Methods. Fig. 3 shows PRO
scores computed from tissue cores (symbols below
dashed lines) and from sections (symbols above dashed
lines) for all 7 patients. Tissue cores and sections derived
from the same block are shown in the same color. Tissue
cores from IDC, DCIS and normal tissue are represented
as circles, diamonds and triangles, respectively. Sections
representing a mixture of more than one tumor type are
depicted as squares. Replicate cores taken from histologi-
cally homogeneous tissue regions gave similar scores (tis-
sue cores from patients 1–5) corroborating that the
Table 2: Gene expression assays used for QRT-PCR
Symbol Gene description Accession No. Category Amplicon Size
GUSB glucuronidase, beta NM_000181.1 Control 81
RPLP0 ribosomal protein, large, P0 NM_053275.3
NM_001002.3
Control 105
UBB ubiquitin B NM_018955.2 Control 120
BCL2 B-cell CLL/lymphoma 2 NM_000633.2 ER 81
ESR1 estrogen receptor 1 NM_000125.2 ER 62
PGR progesterone receptor NM_000926.3 ER 118
SCUBE2 CEGP1, signal peptide, CUB domain, EGF-like 2 NM_020974.1 ER 64
ERBB2 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma 
derived oncogene homolog (avian)
NM_001005862.1
NM_004448.2
Her2 120
GRB7 growth factor receptor-bound protein 7 NM_005310.2 Her2 70
AURKA STK15 aurora kinase A NM_003600.2 Proliferation 85
BIRC5 baculoviral IAP repeat-containing 5 (survivin) NM_001012271.1
NM_001168.2
Proliferation 93
CCNB1 cyclin B1 NM_031966.2 Proliferation 104
MKI67 antigen identified by monoclonal antibody Ki-67 NM_002417.3 Proliferation 131
MYBL2 v-myb myeloblastosis viral oncogene homolog (avian)-like 2 NM_002466.2 Proliferation 81
Shown are genes on the TLDA that were used for computing the PRO, ER and HER2 scores and the three control genes used for normalization [8].Page 4 of 7
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scores were also measured between tissue cores and sec-
tions in cases where blocks contained only one type of
tumor or normal tissue (for example patient 6).
Blocks from several patients contained IDC, DCIS and
normal tissue in the same paraffin block (patients 1, 2 and
4). In all these cases, the PRO scores measured from entire
sections were similar to PRO scores determined from IDC
tissue cores. This is most likely due to a higher RNA con-
tent in tumor cells than in normal breast tissue. Scores
determined from normal tissue cores consistently
revealed low PRO scores while PRO scores were higher for
IDC or DCIS of the same block or from different blocks of
the same patient (patients 1–6). Samples from patient 7
contained IDC which had a relatively low PRO score cor-
responding to cancers which have a more favorable prog-
nosis than cancers which have high PRO scores (Antonov
et al., manuscript in preparation). In all patients PRO
scores were fairly similar for DCIS and IDC. A similar
observation was reported previously by others [14,15]
who compared atypical ductal hyperplasia, DCIS and IDC
and showed high degrees of similarity at the level of gene
expression between these pathological stages. Both stud-
ies were based on fresh frozen material.
Tissue cores used in this study had a length of about 3
mm. To investigate whether the tissue was histologically
homogenous in the vertical dimension, 3 mm of each
block were sectioned and every 400 μm one section was
stained and 5 sections were taken for RNA isolation. In
most cases morphology was similar at different levels (Fig.
Characterization of RNAFigure 2
Characterization of RNA. RNA was isolated from tissue cores and from histological sections and RNA concentration was 
measured spectrophotometrically (A). RNA yield was converted to correspond to 3 tissue cores with an average length of 3 
mm or to 1 tissue section (10 μm thick), respectively. Mean recoveries and corresponding standard deviations are shown for 
17 IDC, 9 DCIS and 12 normal tissue cores (N) and for 40 tissue sections (S). Five RNAs were excluded from subsequent 
experiments because RNA yield was less than 0.45 μg. The quality of each RNA sample was tested on a Bioanalyzer. A repre-
sentative, gel-like picture for each histological type is shown (B). RNA quality was further assessed by QRT-PCR and mean Cts 
of 3 control genes (GUSB, RPLP0 and UBB) are shown (C). One RNA sample from DCIS and 2 RNA samples from normal tis-
sue were excluded from subsequent expression measurement because mean Ct values of control genes were more than one 
standard deviation higher than the mean of all Cts (arrows).Page 5 of 7
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BMC Cancer 2008, 8:343 http://www.biomedcentral.com/1471-2407/8/3431A, C and 1D). Similarly, RNA derived from each layer
gave similar PRO scores (Fig. 3, blocks from patients 1 –
5, upper rows). This is in agreement with other studies,
which showed by TMA and immunohistochemistry that
data generated from tissue cores yield clinically significant
and representative results [16,17]. The PRO score which is
generated from proliferation-related genes was also com-
pared to Ki-67 labeling index which was determined by
PRO scores from tissue cores and from sectionsFigure 3
PRO scores from tissue cores and from sections. PRO scores were computed from tissue cores (symbols below dashed 
lines) and from sections taken at different levels of tissue blocks (symbols above dashed lines). Scores derived from IDC are 
represented by circles, DCIS by diamonds and normal tissue by triangles. Sections containing IDC, DCIS and/or normal tissue 
are shown as squares, sections containing only one tissue type are given with the same symbols as tissue cores. Cores and sec-
tions derived from the same tissue block are shown in the same color.
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BMC Cancer 2008, 8:343 http://www.biomedcentral.com/1471-2407/8/343immunohistochemistry from sections. The PRO scores
determined from tissue cores of IDC and DCIS or from tis-
sue sections in the 7 patients are in good agreement with
Ki-67 labeling index (Table 1 and Fig. 3). Tissue cores
were also evaluated with respect to ER and HER2 scores
confirming that RNA from tissue cores is suitable for gene
expression measurement (data not shown).
Conclusion
The method presented here is suitable for FFPE tissue, it
can be combined with traditional TMA studies without
great additional effort allowing to match molecular mark-
ers with morphological, immunohistochemical and/or in
situ analyses. Comparing stained tissue sections before
and after taking tissue cores allows to control very pre-
cisely whether material was taken from the expected area
and cores representing unwanted tissue regions can be
excluded from further analysis. Sufficient RNA can be iso-
lated from 3 to 5 tissue cores for multiple QRT-PCR anal-
yses (at least 100 reactions) without the need for RNA
amplification.
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